Logo

BioLineRx Reports Results of BL-8040 in Combination with Keytruda (pembrolizumab) in P-IIb Trial for Patients with Metastatic Pancreatic Cancer

Share this

BioLineRx Reports Results of BL-8040 in Combination with Keytruda (pembrolizumab) in P-IIb Trial for Patients with Metastatic Pancreatic Cancer

Shots:

  • The P-IIa study involves assessing of BL-8040 + Keytruda in 20 patients with metastatic pancreatic cancer who progressed after at least one prior line of chemotherapy
  • The overall median time to progression was 2 mos. - while the median time to progression for patients showing disease control was 7 mos. and mOS was 7 mos. - while median survival for the patients showing disease control was 12 mos.- was well-tolerated results plus showed 20% disease control rate
  • BL-8040 is a short synthetic peptide acting as an antagonist for a chemokine receptor CXCR4 and is also being evaluated in P-IIa COMBAT/KEYNOTE-202 study in combination with Keytruda and CT for patients with metastatic pancreatic cancer patients. BioLineRx in-licensed BL-8040 from Biokine Therapeutics

Click here to­ read full press release/ article | Ref: BioLineRx | Image: Twitter


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions